Comparison of real-world healthcare resource utilization among advanced therapy-naïve and -experienced patients with ulcerative colitis initiated on ustekinumab or vedolizumab

References

• Kobayashi T, Siegmund B, Le Berre C, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020;6(1):74.
   Google Scholar
• Ye Y, Manne S, Treem WR, et al. Prevalence of Inflammatory Bowel Disease in Pediatric and Adult Populations: Recent Estimates From Large National Databases in the United States, 2007–2016. Inflammatory Bowel Diseases. 2019;26(4):619-625.
   Google Scholar
• Crohn’s & Colitis Foundation of America. 2014 [cited May 15, 2018]. Available from: http://www.crohnscolitisfoundation.org/assets/pdfs/updatedibdfactbook.pdf
   Google Scholar
• Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012;380(9853):1606-19.
   Google Scholar
• Armuzzi A, Liguori G. Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review. Digestive and Liver Disease. 2021;53(7):803-808.
   Google Scholar
• Irvine JE. Quality of life of patients with ulcerative colitis: Past, present, and future. Inflammatory Bowel Diseases. 2007;14(4):554-565.
   Google Scholar
• Fumery M, Singh S, Dulai PS, et al. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. Clin Gastroenterol Hepatol. 2018;16(3):343-356.e3.
   Google Scholar
• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389(10080):1756-1770.
   Google Scholar
• Cohen R, Skup M, Ozbay AB, et al. Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US. J Med Econ. 2015;18(6):447-56.
   Google Scholar
• Pilon D, Ding Z, Muser E, et al. Long-term direct and indirect costs of ulcerative colitis in a privately-insured United States population. Current Medical Research and Opinion. 2020;36(8):1285-1294.
   Google Scholar
• Wong G, Solon C, Way N, et al. S3186 Healthcare Resource Utilization Increases With Disease Severity in Ulcerative Colitis in the USA: The National Health and Wellness Survey. ACG. 2020;115:S1673-S1674.
   Google Scholar
• Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG Clinical Guideline: Ulcerative Colitis in Adults. ACG. 2019;114(3):384-413.
   Google Scholar
• Segal JP, LeBlanc JF, Hart AL. Ulcerative colitis: an update. Clin Med (Lond). 2021;21(2):135-139.
   Google Scholar
• Kayal M, Shah S. Ulcerative Colitis: Current and Emerging Treatment Strategies. J Clin Med. 2019;9(1).
   Google Scholar
• Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020;158(5):1450-1461.
   Google Scholar
• ENTYVIO® (vedolizumab) Prescribing Information: United States Food and Drug Administration; 2023. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761133s000lbl.pdf
   Google Scholar
• STELARA® (ustekinumab) Prescribing Information: United States Food and Drug Administration; 2023. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761044s009lbl.pdf
   Google Scholar
• Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine. 2019;381(13):1201-1214.
   Google Scholar
• Zhdanava M, Ding Z, Manceur AM, et al. Treatment persistence among bio-naive patients with Crohn's disease initiated on ustekinumab or adalimumab. Curr Med Res Opin. 2023;39(4):533-543.
   Google Scholar
• Zhdanava M, Zhao R, Manceur AM, et al. Persistence and other treatment patterns among bio-experienced patients with Crohn’s disease initiated on ustekinumab or adalimumab. J Manag Care Spec. 2023;29(8):907-916.
   Google Scholar
• Austin PC. Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research. Commun Stat - Simul Comput. 2009;38(6):1228-1234.
   Google Scholar
• Cichewicz A, Tencer T, Gupte-Singh K, et al. A Systematic Review of the Economic and Health-Related Quality of Life Impact of Advanced Therapies Used to Treat Moderate-to-Severe Ulcerative Colitis. Adv Ther. 2023;40(5):2116-2146.
   Google Scholar
• Chiorean M, Afzali A, Cross RK, et al. Economic Outcomes of Inflammatory Bowel Disease Patients Switching to a Second Anti-Tumor Necrosis Factor or Vedolizumab. Crohns Colitis 360. 2020;2(2).
   Google Scholar
• Bessissow T, Narula N, Ma C, et al. EE227 Healthcare Resource Utilization and Costs Among Patients with Moderately-to-Severely Active Crohn's Disease Treated with Ustekinumab: Real-World Evidence. Value in Health. 2022;25(12):S97-S98.
   Google Scholar
• Obando C, Ding Z, Muser E, et al. Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn’s Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States. Advances in Therapy. 2020;37(5):2127-2143.
   Google Scholar
• Yang H, Huang Z, Li M, et al. Comparative effectiveness of ustekinumab vs. vedolizumab for anti-TNF-naive or anti-TNF-exposed Crohn's disease: a multicenter cohort study. eClinicalMedicine. 2023;66.
   Google Scholar
• Biemans VBC, van der Woude CJ, Dijkstra G, et al. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment. Aliment Pharmacol Ther. 2020;52(1):123-134.
   Google Scholar
• Alric H, Amiot A, Kirchgesner J, et al. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor. Aliment Pharmacol Ther. 2020;51(10):948-957.
   Google Scholar